How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of age, disability, gender reassignment, pregnancy and maternity, race, religion or belief, sex or sexual orientation?

Draft guidance consultation

Open for comments Open until   Request commenting lead permission

We have updated this service so that members of the same organisation can now collaborate on a joint online response.

Read our blog to learn more.

1 Recommendations

1.1

Fenfluramine is not recommended, within its marketing authorisation, for treating seizures associated with Lennox–Gastaut syndrome (LGS) as an add-on to other antiseizure medicines for people 2 years and over.

1.2

This recommendation is not intended to affect treatment with fenfluramine that was started in the NHS before this guidance was published. People having treatment outside this recommendation may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS healthcare professional consider it appropriate to stop. For children or young people, this decision should be made jointly by the healthcare professional, the child or young person, and their parents or carers.

Why the committee made these recommendations

People with LGS are offered a range of antiseizure medicines. If this does not control their seizures, other treatments can be introduced, including cannabidiol plus clobazam.

Evidence from a clinical trial shows that people who have fenfluramine have fewer drop seizures per month than people who have standard care without cannabidiol plus clobazam. There is no evidence directly comparing fenfluramine with cannabidiol plus clobazam. The results of an indirect comparison comparing fenfluramine with cannabidiol plus clobazam are uncertain.

The economic evidence for fenfluramine has some uncertainties, including how well it works in the long term and around some of the assumptions used to estimate cost effectiveness. Even when considering the condition's severity and its effect on quality and length of life, the most likely cost-effectiveness estimates are highly uncertain and above what NICE considers an acceptable use of NHS resources. So, fenfluramine is not recommended.